ANIP - NASDAQ
ANI Pharmaceuticals, Inc.
$75.23
-1.9%ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
At a Glance
Live Snapshotanip
Research Development Expenses
Last Annual Value
51.66M
3-Year CAGR
32%
5-Year CAGR
26%
10-Year CAGR
33%
ANI Pharmaceuticals, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
ANI Pharmaceuticals, Inc. NASDAQ:ANIP | 51.66M | 14.6% | 35.4% | 33.3% | |
 Harrow Health, Inc. NASDAQ:HROW | 15.05M | 31.3% | 6.3% | 35.2% |
ANI Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your ANIP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.